1.
Ravasio R, Antonelli S, Maiorino A, Costanzo A, Losi S. Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy. GRHTA [Internet]. 7Jan.2019 [cited 2Apr.2020];6(1). Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/468